Back to results
US 2026/0217697 A1Published application
Compounds comprising heteroaryl rings and compositions and methods thereof
AssigneelonGen Therapeutics Co., Ltd.
InventorsXiaoguang Lei, Daohong Liao, Yong Yang, Linghan Hu, Shun Su
Life of this patent
Estimating the term…
Abstract
Among other things, the present disclosure provides compounds of formula I or salts thereof. In some embodiments, provided compounds are useful as TRPV3 inhibitors. In some embodiments, the present disclosure provides methods for preventing or treating TRPV3-associated conditions, disorders or diseases.
Claims44
A compound, wherein the compound has the structure of formula I:
- or a salt thereof, wherein:
- Ring A is an optionally substituted 5-6 membered aromatic ring having 0-4 heteroatoms, or is
- each of X1, X2a, X2b, and X2c is independently —N═, —C(R2)═ or optionally substituted —CH═;
- X1a is —O—, —S—, —N(R′)—, —C(R′)2—, or optionally substituted —CH2— or —NH—;
- X3 is —O—, —S—, —Se—, —N(R′)— or optionally substituted —NH—;
- each of X4, X5, X6, X7 and X8 is independently —N═, —C(R6)═ or optionally substituted —CH═;
- each of R1, R2, Rs and R6 is independently halogen, —CN, —NO2, -L-R′, —OR′, —N(R′)2, —N(R′)C(O)OR′, —C(O)R′, —C(O)OR′, —C(O)N(R′)2, or —OC(O)N(R′)2;
- L1 is a covalent bond, —C(O)—, —C(S)—, —S(O)2—, —N(R′)C(O)—, —N(R′)S(O)2—, —N(R′)C(S)— or
- each of R3, R4 and R5 is independently R′;
- each of L and L2 is independently optionally substituted C1-3 alkylene, wherein one or more methylene units of the alkylene are optionally and independently replaced with —O—, —S—, —C(R4)(R5)—, —N(R4)—, optionally substituted —CH═N—, optionally substituted —CH═CH— or -Cy-;
- each -Cy- is independently wherein Ring B is an optionally substituted saturated or partially saturated 3-10 membered ring having 0-4 heteroatoms;
- t is 0, 1, 2, 3 or 4;
- each R′ is independently R, —OR, —C(O)R, —C(O)OR, or —S(O)2R;
- each R is independently hydrogen or an optionally substituted group selected from C1-C10 aliphatic, C1-C10 heteroaliphatic having 1-3 heteroatoms, 3-10 membered cycloaliphatic, 3-10 membered heterocyclyl having 1-4 heteroatoms, 6-10 membered aryl, 5-10 membered heteroaryl having 1-6 heteroatoms, 6-10 membered aryl-C1-C10 aliphatic, and 5-10 membered heteroaryl having 1-6 heteroatoms-C1-C10 aliphatic;
- or
- two R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted 3-10 membered ring having, in addition to the atom, 0-4 heteroatoms;
- or
- two R groups on two atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having, in addition to the intervening atoms, 0-4 heteroatoms.
15 more elements
A compound, wherein the compound is selected from
- or a salt thereof.
A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.